Ms. Terri R Ford-wolfgram, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 110 N 16th St Ste 16, Norfolk, NE 68701 Phone: 402-644-7314 Fax: 402-644-7315 |
Diane A Martin, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 1306 N 13th St, Norfolk, NE 68701 Phone: 402-371-8218 Fax: 402-371-8259 |
Denise L Serres, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 1306 N 13th St, Norfolk, NE 68701 Phone: 402-371-8218 Fax: 402-371-8259 |
Nikki Hendrickson, PCMSW, PLMHP Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 100 W Norfolk Ave, Norfolk, NE 68701 Phone: 308-991-0873 |
Kristine Rose Boe Simmons, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1700 N Victory Rd, Box 1209, Norfolk, NE 68701 Phone: 402-370-3400 |
News Archive
Icagen, Inc. today announced that, following a review of data from recently completed clinical studies as well as the Company's proposed protocol for a Phase II clinical trial in patients with treatment resistant epilepsy, the FDA has notified the Company that the clinical hold on Icagen's IND for ICA-105665, a novel orally available small molecule KCNQ potassium channel agonist, has been removed.
A team of scientists from Johns Hopkins and elsewhere have developed nano-devices that successfully cross the brain-blood barrier and deliver a drug that tames brain-damaging inflammation in rabbits with cerebral palsy.
Childhood obesity in the United States is an epidemic - nationwide, 19 percent of children ages 6 to 11 and 17 percent of those 12 to 19 are overweight, according to the Centers for Disease Control and Prevention (CDC). Those who are overweight during childhood also have an increased risk of obesity in adulthood and are at greater risk for complications such as diabetes, high blood pressure and heart disease, because obesity increases total blood volume, which leads to extra stress on the heart.
NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces a successful meeting with the US Food and Drug Administration (FDA) to discuss the Company's clinical development of its Aganocide compound NVC-422, intended for use in the treatment of impetigo.
› Verified 4 days ago